Biovation Signs Research Agreement With Centocor
Dr. Frank Carr, President and Chief Executive Officer of Biovation, commented, "We are delighted to be working with Centocor, a pioneer in the immunotherapy of human diseases. This is an excellent opportunity for us to extend the application of DeImmunisation and produce further clinical products."
DeImmunisation represents an entirely different approach to reducing immunogenicity. The technology addresses a major driver of immunogenicity in therapeutic antibodies and proteins, namely T cell epitopes. The DeImmunisation technology involves the identification and removal of T cell epitopes from the molecule. Since potentially immunogenic regions of the molecule are removed by single amino acid substitutions, immunogenicity can be eliminated while retaining the properties of the starting molecule.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous